Mobility FLEX [™] : Any age, any stage		
WEIGHT		61+ POUNDS
PROPRIETARY BLEND (Corydalis Yanhusuo Rhizome, Devil's Claw (Harpagophytum procumbens) Extract, Boswellia serrata Extract, Bromelain)	785 mg	1570 mg
METHYLSULFONYLMETHANE (MSM)	250 mg	500 mg
PERNA CANALICULUS (GlycOmega™ brand Green-Lipped Mussel)	250 mg	500 mg
RST 247 (Proprietary Oil Blend, Soy Lecithin, Cranberry Powder)	50 mg	100 mg
DIRECTIONS FOR USE	0-30 lbs: 1 chew daily 31-60 lbs: 2 chew daily 61+ lbs: 4 chews daily	61+ lbs: 2 chews daily
	0000500 060	0000708 060

1 Clin Pharmacokinet. 2011 Jun;50(6):349-69. doi: 10.2165/11586800-00000000-00000. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Abdel-Tawab M1, Werz O, Schubert-Zsilavecz M.

2 Phytother Res. 2012 Jun;26(6):806-11. doi: 10.1002/ptr.3636. Epub 2011 Nov 10. Molecular targets of the antiinflammatory Harpagophytum procumbens (devil's claw): inhibition of TNFα and COX-2 gene expression by preventing activation of AP-1. Fiebich BL1, Muñoz E, Rose T, Weiss G, McGregor GP.

3 Nan Fang Yi Ke Da Xue Xue Bao. 2010 Sep;30(9):2161-4. [Analgesic effect of Corydalis yanhusuo in a rat model of trigeminal neuropathic pain]. [Article in Chinese] Huang JY1, Fang M, Li YJ, Ma YQ, Cai XH.

4 Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M. Oral enzyme combination versus diclofenac in the treatment o osteoarthritis of the knee—a double-blind prospective randomized study. Clin Rheumatol. 2004 Oct;23(5):410-5.

5 Huang J, Fang M, Li Y, Ma Y, Cai X. Analgesic effect of Corydalis yanhusuo in a rate model of trigeminal neuropath ic pain. J South Med Univ 2010;30(9):2161

6 Kubo M, Matsuda H, Tokuoka K, Ma S, Shiomoto H. Anti-inflammatory activities of methanolic extract and alkaloidal components from Corydalis tuber. Biol Pharm Bull 1994b;17:262-265.

7 Reichling J, Schmokel H, Fitzi J, et al. Dietary support with Boswellia resin in canine inflammatory joint and spinal disease. Schweiz Arch Tierheilkd 2004;146:71-79.

8 Klein G, Kullich W, Schnitker J, Schwann H. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp. Rheumatol. 2006 Jan-Feb;24(1):25-30.

 Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytother Res. 2007 Jul;21(7):675-83.

10 Grant L, McBean DE, Fyfe L, Warnock AM. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytother Res. 2007 Mar;21(3):199-209.

11 Brien S, Lewith GT, McGregor G. Devil's Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: review of efficacy and safety. J Altern Complement Med. 2006 Dec;12(10):981-93.

12 Vieira, C,. Ferzer S., Sauer S.K., Evangelista S.E., Averbeck B., Kress M., Reeh P.W., Cirillo R., Lippi A., Maggi C.A., and Manzini S. 2001. Pro- and anti- inflammatory actions of ricinoleic acid: similarities and differences with capsaicin. Naunyn-Schmiedeberg's Arch. Pharmacol., 364: 87-95



13 Novak, A.F., G.C. Clark, and H.P. Dupuy. 1961. The antimicrobial activity of some ricinoleic and oleic acid derivatives. J. Amer. Oil. Chem. Soc. 38:321-324.

14 NTP 1992. Toxicity studies of castor oil in F344/N rats and B6C3F1 mice (dosed feed studies). National Toxicology Program (NTP), Research Triangle Park, NC. Report Number: NTIS PB93-151439.

15 Martinez S, McCormick D, Powers M, Davies N, Yanez J, Hughes K and Lincoln J. The effects of Glyco FLEX® 3 on a stable stifle osteoarthritis model in dogs: a pilot study. Washington State University, 2006. Presented at NAVC 2007.







1.800.882.9993

www.vetriproline.com





STRENGTH & COMFORT

LIFE UNINTERRUPTED

RST 247 Platform:

Th1

Mobility FLEX[™] is recommended for acute or chronic joint and muscloskeletal comfort – especially that occurring after surgery or trauma – either as an independent choice or a complement to current protocol.



- » Mobility FLEX™ features VetriScience[®]'s Herbal Comfort Complex – a proprietary blend of Bromelain, Boswellia, Corydalis, and Devil's Claw. These constituents have long been studied for their anti-inflammatory properties.^{1,2,3,4}
- » The most actively studied alkaloid in Corydalis, tetrahydropalmatine (THD), has demonstrated many pharmacological actions on the central nervous system. It has been effective in reducing nerve pain, abdominal pain and headache.⁵ The mechanism of action appears to involve opioid, GABA-ergic, dopaminergic and cannabanoid receptors.6
- » A prospective, open, multicenter, clinical trial in dogs with osteoarthritis utilized a standardized Boswellia resin extract. Overall, 71% of the dogs that were assessed exhibited "good" or "very good" results at two and six weeks of treatment. Investigators claimed that after six weeks, anywhere from 40% to 70% of the dogs were symptom-free.⁷
- » The use of Devil's Claw in clinical trials has supported its efficacy in the treatment of acute and chronic pain.⁹ In high quality human clinical trials, Devil's Claw has been as effective as NSAIDs in alleviating low back pain and pain due to hip and knee arthritis.^{9, 10} Comparative trials suggested that Devil's Claw is also as safe or safer than NSAID therapy, and no clinical interactions with drugs used in the treatment of arthritic conditions have been reported.¹¹
- » Bromelain is a complex of proteolytic enzymes, glycoproteins, and proteinase inhibitors extracted from pineapple. It has been shown (in a formula with another proteolytic enzyme) to have anti-inflammatory activity clinically equivalent to that of the NSAID, diclofenac.^{4, 8}

Mobility FLEX™ contains RST 247 — a unique blend of three, cold-pressed oils supplying unsaponifiable lipids, which have been shown to reduce inflammation.¹²

- » Ricinoleic Acid, a major component of RST 247, has been shown to act upon certain bacteria and fungi, thus promoting a healthy microbial environment in the gut, which supports optimal ingredient absorption and utilization.¹³
- 7500 mg/kg/day and 5000 mg/kg/day in mice and rats, respectively.¹⁴
- contribute support to mediating the Th1 response and effecting balance.

Perna canaliculus:



- level of the animals.¹⁵

VLS 240

Mani S. and Lawson J. In vitro modulation of inflammatory cytokine and IgG levels of Perna canaliculus. BMC Complement Alternative Med., 2006; 6:1.

The purpose of the study was to evaluate how Perna canaliculus may reduce inflammation. Perna demonstrated reduction of certain inflammatory pathways including those involving cytokines (TNF-alpha, IL-1, IL-2 and IL-6), cycloxygenase enzyme (COX-2), and IgG (immunoglobulin G), suggesting that Perna may have a role in reducing inflammation.

Summary:

- » Perna inhibited IgG production and reduced pro-inflammatory cytokines TNF-alpha, IL-1, IL-2 and IL-6 in cell culture models.
- » Perna inhibits the COX-2 enzyme system.
- » Results demonstrate possible mechanisms by which Perna can modulate inflammatory mediators.



» GlycOmega™ brand Perna canaliculus is a great source of EFAs, hyaluronic acid and chondroitin sulfates.

» Clinical trials with dogs, cats, and horses have led to evidence that Perna canaliculus supports mobility, range of motion, and the overall comfort

» Perna's natural constituents support synovial fluid viscosity and tensile strength of the articular cartilage.

